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Background
• Aurora-A kinase (AA) and Polo-like 
kinase (PLK) are implicated in the 
tumorigenesis of solid tumors 
and, recently, in B- and T-cell non 
Hodgkin lymphomas (NHL)
• They play a key role in tumor 
proliferation and disease 
progression in highly aggressive B-
cell NHL
• They also serve as indicators of 
disease activity and are thus 
attractive therapeutic targets
Study Goals
• This study assesses AA and PLK expression in different Classic 
Hodgkin Lymphoma (CHL) types, such as nodular sclerosis type, 
mixed cellularity type, and lymphocyte rich type, and their mimics: 
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and 
primary mediastinal B-cell lymphoma (PMBL)
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Design
• 27 classic Hodgkin lymphoma cases, 16 nodular lymphocyte predominant 
Hodgkin lymphoma cases, and 8 primary mediastinal B-cell lymphoma cases 
were assessed for Aurora-A kinase and Polo-like kinase expression by 
immunohistochemistry (IHC)
• CHL cases included the following: 8 mixed cellularity CHL, 1 lymphocyte rich 
CHL, and 18 nodular sclerosis CHL
• A mouse monoclonal AA-antibody (1:1000 dilution, Abcam, UK) and a PLK-
antibody (1:500 dilution, Cell Signaling Technologies, USA) were used
• Each case was semi-quantitatively graded for percentage of positive cells (<50% 
vs. >50%), for staining intensity (1-3+), and for localization (nuclear vs. 
cytoplasmic)
• IHC analysis was performed by 2 pathologists (KMH and KVI)
• Statistical analysis was performed using Fisher’s exact test
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Aurora-A and Polo-like kinase were expressed 
in classic Hodgkin lymphoma but not primary 
mediastinal B-cell lymphoma
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Aurora-A and Polo-like Kinase were expressed in 
nodular lymphocyte predominant Hodgkin 
lymphoma but not in primary mediastinal B-cell 
lymphoma
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Tumor Cells with >50% PLK 
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p = 0.044
Low Stage Disease (I-II) 5 1
High Stage Disease (III-
IV) 1 8
Polo-like kinase expression correlated with 
higher stage disease at presentation in nodular 
lymphocyte predominant Hodgkin lymphoma
Conclusion
•Aurora-A and Polo-like kinase are commonly expressed in classic 
Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin 
lymphoma but not in primary mediastinal B-cell lymphoma. Thus, 
they are useful markers in the distinction of CHL or NLPHL from 
PMBL.
•PLK is a useful marker for the prognostication of NLPHL
•AA and PLK are attractive potential therapeutic targets in the 
treatment of CHL and NLPHL
•Additional studies are underway to characterize an array of 
hematopoietic lesions known to overlap with CHL
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